Skip to main content

Press Releases

November 18, 2020

BERKELEY, CA – November 18, 2020 – Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the execution of an exclusive license agreement with Memorial Sloan Kettering Cancer Center (MSK) under which Caribou has rights to fully human anti-CD371 scFvs and intellectual property related thereto in the field of allogeneic CD371-targeted cell therapies including CAR-T, CAR-NK, or iPSC-derived cell products. The anti-CD371 scFvs were developed in the laboratory of Renier Brentjens, M.D., Ph.D.

October 7, 2020

BERKELEY, CA – October 7, 2020 – Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, today announced that co-founder Jennifer Doudna, Ph.D., has been awarded the 2020 Nobel Prize in Chemistry. In awarding the prize to Dr. Doudna, the Swedish Academy cited her contributions to science for the co-development of CRISPR-Cas9, a genome editing breakthrough which has revolutionized biomedicine.

In the News

Harnessing Type I CRISPR–Cas systems for genome engineering in human cells

November 19, 2019

Using a FokI fusion design, we show that Type I CRISPR-Cas systems can be expressed, reconstituted, and faithfully trafficked to the nucleus for genome engineering in human cells.

This Scientist Turned CEO Wants to Gene-Edit a Way to Cure Cancer

March 16, 2018

In a fashionable fitted blazer, Rachel Haurwitz looks the part of a polished executive when she meets me in the largest conference room of her company, Caribou Biosciences. She’s sharp and tactical as she speaks, even though it was just a few years ago that Haurwitz traded her lab coat for a tailored suit and stepped up to lead a staff of 46 as Caribou’s CEO.

About Us

Pioneering the translation of CRISPR-Cas genome engineering into new medical therapies and bio-based products. Learn more. 

Contact Us

For media and investor inquiries and general information, click here.

Follow Us

Connect with us on Twitter for the latest news and updates. Click here.

Media Contact

Greg Kelley
Senior Vice President
Feinstein Kean Healthcare
(404) 836-2302